Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver patients get brain protection: antibiotic may stop confusion after TIPS

NCT ID NCT02016196

Prevention Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the antibiotic rifaximin could prevent a serious brain condition called hepatic encephalopathy in people with cirrhosis who undergo a TIPS procedure. The TIPS procedure helps reduce pressure in the liver but often leads to confusion and other brain issues. The trial involved 211 participants and compared rifaximin to a placebo to see if it could lower the risk of these brain complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

211 people

The number who actually took part.

Started

Sep 2013

Finished

Jul 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * cirrhosis with TIPS for ascit treatment or hydrothorax * prevention digestive bleeding follow up portal hypertension - * signed consent Exclusion Criteria: * hepatocellular carcinoma out of Milan criteria or palliative phase cancer * Child Pugh score \> 12 * TIPS indicated for other indication than bellow * encephalopathy signs : asterixis or confusion * Hypersensibility to rifaximin, or derivated of rifamycin * Patients treated by same class antibacterial * pregnant woman * Patient with hepatic transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hepatic encephalopathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis

Contacts and locations

Locations

  • CHRU Lille

    Lille, France

  • CHU Angers

    Angers, France

  • CHU Beaujon Clichy

    Paris, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Marseille

    Marseille, France

  • CHU Nantes

    Nantes, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rennes

    Rennes, France

  • CHU Saint-Antoine

    Paris, France

  • CHU Tours

    Tours, France

  • Hôpital Jean Verdier

    Bondy, France

  • Pitié Salpêtrière

    Paris, France

  • UHToulouse

    Toulouse, France, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.